Sage Therapeutics(SAGE) - Get Report led biotech movers Friday morning, after its CEO made an erroneous comment during an interview about its depression drug, Thursday after the close. 

Sage spiked 8.9% Thursday on the comment, hitting $62.75 per share. CEO Jeff Jonas said the company is on top of everyone's M&A list in an interview with Bloomberg radio. 

The company issued a statement  after the stock pop, saying Sage is not in any talks to sell. As a result, Sage's stock was correcting its Thursday pop Friday morning, falling 4.16% to $60.14 per share. 

Novavax(NVAX) - Get Report was also falling Friday morning. The company's shares fell 1.28% to $1.54 per share Friday ahead of the market's open. This continued the vaccine company's Thursday fall of 3.7%. It closed at $1.56 per share Thursday. 

Meanwhile, Cytokinetics(CYTK) - Get Report shares were flying high Friday. The company was up 7.5% ahead of market's open, shares hitting $12.15 apiece. This was after Cytokinetics, a muscle therapy company, reported better-than-expected fourth-quarter earnings. Cytokinetics had a profit of 16 cents per share, as compared to analysts' expectations of a loss of 27 cents a share. 

Acadia Pharmaceuticals(ACAD) - Get Report was falling Friday morning, hitting $38.45 per share. The Parkinson's disease biotech company fell nearly 2% ahead of market's open. Acadia was the target of takeout rumors earlier this week. However, TheStreet'sAdam Feuerstein was skeptical on those rumors.